Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors

Acta Biochimica Polonica

Volumn 56, Issue 1, 2009, Pages 161-165

  Mitrus, Iwona ^a   Sochanik, Aleksander ^a   Cichoń, Tomasz ^a   Szala, Stanisław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

CA4P; Combined therapy; Doxorubicin; Liposomes

Indexed keywords

MURINAE;

EID: 67249095624     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2009_2528     Document Type: Article

References (18)

1. Bartlett GR (1958) Phosphorus assay in column chromatography. J Biol Chem 234: 466-468.
2. Gabizon AA, Shmeeda H, Zalipsky S (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16: 175-183.
3. Gaukroger K, Hadfield JA, Hepworth LA, Lawrence NJ, McGown AT (2001) Novel syntheses of cis and trans isomers of combretastatin A-4. J Org Chem 66: 8135-8138.
4. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539.
5. Kanthou C, Tozer GM (2007) Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 11: 1443-1457.
6. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
7. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63: 7400-7409.
8. Ribatti D, Nico B, Crivellato E, Vacca A (2007) The structure of the vascular network of tumors. Cancer Lett 248: 18-23.
9. Salmon BA, Siemann DW (2007) Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 68: 211-217.
10. Shi W, Horsman MR, Siemann DW (2006) Combined modality approaches using vasculature-disrupting agents. In Vascular-targeted Therapies in Oncology, Siemann DW, ed, pp 123-136. Chichester. John Wiley & Sons Ltd.
11. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6.
12. Sivridis E, Giatromanolaki A, Koukourakis MI (2003) The vascular network of tumours - what is it not for? J Pathol 201: 173-180.
13. Soloman R, Gabizon AA (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 8: 21-32.
14. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
15. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
16. Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38.
17. West CM, Price P (2004) Combretastatin A4 phosphate. Anticancer Drugs 215: 179-187.
18. Zhou R, Mazurchuk R, Straubinger RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62: 2561-2566.